Oglesby A, et al. Patient-reported outcomes after switching to a two-drug regimen of dolutegravir + rilpivirine: Week 100 results from the SWORD-1 and SWORD-2 studies. Abstract P101. HIV/Drug Therapy Glasgow 2018.
5-alfa-reductaseremmers geassocieerd met minder COVID-19-symptomen bij mannen met alopecia androgenetica
feb 2021 | Virale infecties